Zydus Cadila Explores Orphan Drug Indication For NASH Candidate
Expects 20-25 New Product Launches In FY21
Cadila is exploring orphan indications for saroglitazar magnesium, in addition to the approaching Phase III NASH clinical trials for its lead NCE. Meanwhile, it counts on new product launches and biosimilars to take its FY21 growth story ahead.
